Comparative efficacy and safety of tigecycline vs colistin for Carbapenem-resistant Enterobacteriaceae (CRE) infections in cancer patients
Background: Carbapenem-resistant Enterobacteriaceae (CRE) infections pose a significant threat owing to their high mortality rates and limited treatment options, exacerbated by antibiotic misuse and the spread of resistance genes. Objective: This study aimed to compare the effectiveness, safety, and...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Clinical Epidemiology and Global Health |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213398425000855 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850064079385788416 |
|---|---|
| author | Sai Vaibhavi Gumudavelli Akshay Shelke Pallavi Priya Richa Chauhan Sameer Dhingra |
| author_facet | Sai Vaibhavi Gumudavelli Akshay Shelke Pallavi Priya Richa Chauhan Sameer Dhingra |
| author_sort | Sai Vaibhavi Gumudavelli |
| collection | DOAJ |
| description | Background: Carbapenem-resistant Enterobacteriaceae (CRE) infections pose a significant threat owing to their high mortality rates and limited treatment options, exacerbated by antibiotic misuse and the spread of resistance genes. Objective: This study aimed to compare the effectiveness, safety, and outcomes of tigecycline and colistin in the treatment of CRE infections in cancer patients. Methods: A 9-month prospective observational study was conducted at a tertiary-care cancer hospital in Bihar, India. The study included 150 patients with CRE infections divided into tigecycline (n = 90) and colistin (n = 60) groups. Results: Patients receiving tigecycline had higher levels of direct bilirubin, alkaline phosphatase, and creatinine. However, tigecycline was associated with shorter hospital stays (13.73 vs 17.45 days, p = 0.016) and therapy durations (5.7 vs 7.3 days, p = 0.04). Infection recurrence rates (3.3 % vs. 5 %) and 30-day mortality rates (17.6 % vs. 18.9 %, p = 0.663) were similar between the two groups. Conclusion: Both tigecycline and colistin were effective in treating CRE infections in patients with cancer. Although tigecycline was associated with improved hospital stay and therapy duration, it also showed potential liver and kidney function adverse effects. These findings highlight the need for careful consideration of treatment options for CRE infections in patients with cancer. |
| format | Article |
| id | doaj-art-c54d2c2e7ab04dada0951af580940d81 |
| institution | DOAJ |
| issn | 2213-3984 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical Epidemiology and Global Health |
| spelling | doaj-art-c54d2c2e7ab04dada0951af580940d812025-08-20T02:49:25ZengElsevierClinical Epidemiology and Global Health2213-39842025-05-013310199610.1016/j.cegh.2025.101996Comparative efficacy and safety of tigecycline vs colistin for Carbapenem-resistant Enterobacteriaceae (CRE) infections in cancer patientsSai Vaibhavi Gumudavelli0Akshay Shelke1Pallavi Priya2Richa Chauhan3Sameer Dhingra4Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, Bihar, IndiaDepartment of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, Bihar, IndiaDepartment of Microbiology, Mahavir Cancer Sansthan and Research Centre (MCSRC), Patna, Bihar, IndiaDepartment of Radiotherapy, Mahavir Cancer Sansthan and Research Centre (MCSRC), Patna, Bihar, IndiaDepartment of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, Bihar, India; Corresponding author. Department of Pharmacy Practice National Institute of Pharmaceutical Education and Research, Hajipur, Dist. Vaishali, Bihar, India.Background: Carbapenem-resistant Enterobacteriaceae (CRE) infections pose a significant threat owing to their high mortality rates and limited treatment options, exacerbated by antibiotic misuse and the spread of resistance genes. Objective: This study aimed to compare the effectiveness, safety, and outcomes of tigecycline and colistin in the treatment of CRE infections in cancer patients. Methods: A 9-month prospective observational study was conducted at a tertiary-care cancer hospital in Bihar, India. The study included 150 patients with CRE infections divided into tigecycline (n = 90) and colistin (n = 60) groups. Results: Patients receiving tigecycline had higher levels of direct bilirubin, alkaline phosphatase, and creatinine. However, tigecycline was associated with shorter hospital stays (13.73 vs 17.45 days, p = 0.016) and therapy durations (5.7 vs 7.3 days, p = 0.04). Infection recurrence rates (3.3 % vs. 5 %) and 30-day mortality rates (17.6 % vs. 18.9 %, p = 0.663) were similar between the two groups. Conclusion: Both tigecycline and colistin were effective in treating CRE infections in patients with cancer. Although tigecycline was associated with improved hospital stay and therapy duration, it also showed potential liver and kidney function adverse effects. These findings highlight the need for careful consideration of treatment options for CRE infections in patients with cancer.http://www.sciencedirect.com/science/article/pii/S2213398425000855Antimicrobial resistanceCancerCRETigecyclineColistin |
| spellingShingle | Sai Vaibhavi Gumudavelli Akshay Shelke Pallavi Priya Richa Chauhan Sameer Dhingra Comparative efficacy and safety of tigecycline vs colistin for Carbapenem-resistant Enterobacteriaceae (CRE) infections in cancer patients Clinical Epidemiology and Global Health Antimicrobial resistance Cancer CRE Tigecycline Colistin |
| title | Comparative efficacy and safety of tigecycline vs colistin for Carbapenem-resistant Enterobacteriaceae (CRE) infections in cancer patients |
| title_full | Comparative efficacy and safety of tigecycline vs colistin for Carbapenem-resistant Enterobacteriaceae (CRE) infections in cancer patients |
| title_fullStr | Comparative efficacy and safety of tigecycline vs colistin for Carbapenem-resistant Enterobacteriaceae (CRE) infections in cancer patients |
| title_full_unstemmed | Comparative efficacy and safety of tigecycline vs colistin for Carbapenem-resistant Enterobacteriaceae (CRE) infections in cancer patients |
| title_short | Comparative efficacy and safety of tigecycline vs colistin for Carbapenem-resistant Enterobacteriaceae (CRE) infections in cancer patients |
| title_sort | comparative efficacy and safety of tigecycline vs colistin for carbapenem resistant enterobacteriaceae cre infections in cancer patients |
| topic | Antimicrobial resistance Cancer CRE Tigecycline Colistin |
| url | http://www.sciencedirect.com/science/article/pii/S2213398425000855 |
| work_keys_str_mv | AT saivaibhavigumudavelli comparativeefficacyandsafetyoftigecyclinevscolistinforcarbapenemresistantenterobacteriaceaecreinfectionsincancerpatients AT akshayshelke comparativeefficacyandsafetyoftigecyclinevscolistinforcarbapenemresistantenterobacteriaceaecreinfectionsincancerpatients AT pallavipriya comparativeefficacyandsafetyoftigecyclinevscolistinforcarbapenemresistantenterobacteriaceaecreinfectionsincancerpatients AT richachauhan comparativeefficacyandsafetyoftigecyclinevscolistinforcarbapenemresistantenterobacteriaceaecreinfectionsincancerpatients AT sameerdhingra comparativeefficacyandsafetyoftigecyclinevscolistinforcarbapenemresistantenterobacteriaceaecreinfectionsincancerpatients |